

Tuberculosis Clinical Intensive – Des Moines, IA  
 October 16, 2017

<b>Program Schedule</b>		
		<b>Speakers</b>
8:00-8:25	Registration	
8:25-8:30	<b>Introductions &amp; Course Overview</b>	<b>Allan Lynch Mayo TB Center Staff</b>
8:30-8:45	<b>Epidemiology of Tuberculosis</b> <ul style="list-style-type: none"> <li>• State, Country, Global</li> <li>• Describe the TB epidemic in terms of susceptible groups</li> <li>• Describe major factors that will affect future trends in TB</li> </ul>	<b>State of Iowa Public Health TB Program</b>
8:45-9:30	<b>TB Transmission, Pathogenesis &amp; Infection Control –</b> <ul style="list-style-type: none"> <li>• Describe how TB is transmitted</li> <li>• Describe the natural history of tuberculosis</li> <li>• Describe how TB causes disease</li> <li>• Describe the components of an effective infection control program</li> </ul>	<b>Jeremy Clain, M.D.</b>
9:30-10:15	<b>Diagnosis of Latent and Active Tuberculosis</b> <ul style="list-style-type: none"> <li>• Explain use of TST and IGRA</li> <li>• Describe laboratory methods used for the detection. Identification, genotyping, and drug susceptibility of <i>M. tuberculosis</i></li> <li>• Identify major chest x-rays abnormalities commonly seen in TB</li> </ul>	<b>Douglas Hornick, M.D.</b>
10:15-10:30	<b>Break</b>	
10:30-11:15	<b>Treatment of Latent Tuberculosis</b> <ul style="list-style-type: none"> <li>• Describe the current guidelines for LTBI treatment</li> <li>• Describe monitoring recommendations for patients on LTBI treatment</li> </ul>	<b>Douglas Hornick, M.D.</b>
11:15-12:00	<b>Lunch</b>	
12:00-12:30	<b>Iowa TB Survivors Story- Video</b>	<b>Allan Lynch</b>
12:30-1:15	<b>Treatment of Active Tuberculosis</b> <ul style="list-style-type: none"> <li>• Identify the basic principles of treatment for active tuberculosis</li> <li>• Describe the current guidelines for the treatment of TB disease</li> </ul>	<b>Jeremy Clain, M.D.</b>
1:15-1:45	<b>Biologics and Tuberculosis</b> <ul style="list-style-type: none"> <li>• Describe concept of immunomodulatory drugs (IMiDs) and development of biologics</li> <li>• Review TNF inhibitors</li> <li>• Identify screening recommendations and controversies</li> </ul>	<b>Claudia Dobler, MD, Ph.D.</b>
1:45-2:15	<b>Diabetes and Tuberculosis</b> <ul style="list-style-type: none"> <li>• Describe impact of diabetes on TB</li> <li>• Describe impact of TB on diabetes</li> </ul>	<b>Claudia Dobler, MD, Ph.D.</b>
2:15-2:30	<b>Break</b>	

Tuberculosis Clinical Intensive – Des Moines, IA  
October 16, 2017

2:30-3:00	<b>Pediatrics and Tuberculosis</b> <ul style="list-style-type: none"><li>• Describe the epidemiology of pediatric TB in the US</li><li>• Describe the clinical presentation of TB in children</li><li>• Describe treatment regimens for pediatric LTBI and active TB</li></ul>	<b>Ritu Banerjee, M.D.</b>
3:00-3:30	<b>Mental Health and Tuberculosis</b> <ul style="list-style-type: none"><li>• Describe historical parallels between tuberculosis and mental illness</li><li>• Identify drug-drug interactions of concern when prescribing medications to treat tuberculosis to patients with mental illness</li><li>• Identify and manage challenges arising from comorbid mental illness/substance use disorders that patients may face when confronting tuberculosis treatment</li></ul>	<b>Robert Morgan, M.D., Ph.D.</b>
3:30-4:00	<b>Resource Review, Course Wrap-up</b>	<b>Mayo TB Center Staff</b>